PRESS RELEASE
04 August 2026 10:00:00 CEST

Cantargia to host Q2 2026 Interim Results Conference Call

Cantargia AB (publ), "Cantargia" (Nasdaq Stockholm: CANTA) will publish its interim report for January – June 2026 on Wednesday, August 19, 2026, at 07:00 a. m. CEST.

Interested investors, analysts, and media are invited to Cantargia's quarterly conference call on the same date at 3:00 p.m. CEST. The event will be hosted by Cantargia's CEO Hilde Steineger and CFO Patrik Renblad. During the call, management will review the Company's interim financial results and provide a business and pipeline update. The presentation will be held in English.

If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: **https://cantargia.events.inderes.com/q2-report-2026**.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/cantargia/q2-report-2026/dial-in.

The webcast and the presentation will also be available on demand on Cantargia's corporate website: **www.cantargia.com**

For further information, please contact
Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: **info@cantargia.com**

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at **www.cantargia.com**.

Attachments

Cantargia to host Q2 2026 Interim Results Conference Call